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Background: Human papillomavirus type 97 (HPV97) DNA was detected in nearly 5% of anal samples collected
from HIV-seropositive men living in Montreal, Canada. The rate of detection of HPV97 in the genital tract of
Canadian women is unknown. Whether HPV97 is a local epidemic in HIV-seropositive men living in Montreal is also
unknown. The prevalence of human papillomavirus type 97 (HPV97) was assessed in cervicovaginal cells from
women living in Canada and in anal samples from HIV-seropositive men living in Toronto.
Findings: Cervicovaginal lavages collected from 904 women (678 HIV-seropositive, 226 HIV-seronegative) women
living in Canada and anal cells collected from 123 HIV-seropositive men living in Toronto were tested for the
presence of HPV97 with PCR. HPV97-positive samples were further tested by PCR-sequencing for molecular variant
analysis to assess if all HPV97-positive men were infected with the same strain. All cervicovaginal samples were
negative for HPV97. HPV97 was detected in anal samples from 6 HIV-seropositive men (4.9%, 95% confidence
interval 2.0-10.5%), of whom five had high-grade and one had low-grade anal intraepithelial neoplasia, in addition
to 2 to 8 HPV genital genotypes per sample. Four HPV97 variants were defined by four variation sites in the viral
control region.
Conclusion: These findings indicate that HPV97 infects in the anal canal of HIV-seropositive men but is not
detected in the genital tract of women.
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HPV97 is a recently characterized HPV genital genotype
related genetically to genotypes 18 and 45 and classified
in the high-risk alpha 7 species [1]. Although HPV97
has been detected with other high-risk genotypes in bi-
opsies with high-grade anal intraepithelial neoplasia
(AIN), it has not been formally associated yet in* Correspondence: francois.coutlee@ssss.gouv.qc.ca
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reproduction in any medium, provided the orepidemiological studies with high-grade anogenital dis-
ease [2]. HPV97 has been detected in the anal canal of
12 (4.9%) of 247 adult HIV-seropositive men living in
Montreal, Canada [2]. In contrast to these results,
HPV97 was detected only rarely in women living in the
United States or Costa Rica [1].
Is HPV97 infection confined to HIV-seropositive men
living in Montreal? To answer this question, we set out
to assess if HPV97 DNA could be detected in cervicova-
ginal lavages collected from women living in Canada at
high-risk of or infected with HIV. We also explored if
HPV97 infection could be detected in the anal canal of
HIV-seropositive men living in another Canadian city byLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Polymorphism of the LCR in 18 HPV97 isolates
LCR variation at nucleotide position
LCR VARIANTS 7 7 7 7 Frequency
1 2 2 4
9 2 8 4
4 0 0 6
reference C A G C
variation T G C T
Prototype C A G C 0
97-LCR-MTL-1 T - C - 1
97-LCR-MTL-2 T - - - 15
97-LCR-MTL-3 T G - - 1
97-LCR-TOR-1 T - - T 1
The prototype is the first isolate that has been sequenced (Chen and Burk, 31
may 2006, HPV 97, accession number DQ080080).
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men living from Toronto.
Results
HPV97 detection in women living in Canada
Women participating in the Canadian Women’s HIV
study have been presented previously [3]. Of the 1055
women participating in that study, 732 were HIV-
seropositive. A sample was not available for 54 partici-
pants, leaving 678 cervicovaginal lavages (CVL) from 678
HIV-seropositive women available for HPV97 testing (282
from Quebec of whom 258 lived in Montreal, 216 from
Ontario, 128 from British Columbia, 25 from Alberta, 15
from Saskatchewan and 12 from Nova Scotia). Of the 323
HIV-seronegative controls recruited in the study, 226
came from Montreal and all were tested for HPV97.
Of the 904 ß-globin-positive CVL lysates tested, none
(0%, 95% confidence interval 0–0.5%) contained HPV97
DNA. Twenty eight of these samples were further ana-
lyzed by nested PCR and all remained negative for
HPV97. The detection limit of the PCR assay was five
copies of HPV97 DNA and one copy of the same viral
DNA when using the nested approach.
HPV97 detection in men living in Toronto
In order to assess if HPV97 causes an epidemic only in
men living in Montreal, anal cytology lysates from 123
HIV-seropositive men living in Toronto were tested for
HPV97. All samples were ß-globin-positive and had been
tested for genital HPV infection with a consensus L1
PCR assay. They contained a median of 4 HPV genotypes
per sample (range, 1 to 11). The most frequent HPV gen-
otypes were HPV16 (n = 49), HPV6 (n = 31) and HPV53
(n = 30). Six anal lysates (4.9%, 95% confidence interval
2.0%-10.5%) tested positive for HPV97 by PCR. The pres-
ence of HPV97 DNA in these samples was confirmed by
restriction enzyme digestion and by PCR-sequencing.
Five of the HPV97-positive samples were from men with
high-grade AIN while one was from a man with low-
grade AIN. The samples from men with AIN also con-
tained from 2 to 8 additional genital HPV genotypes per
sample (median of 5). oncogenic genotypes detected in
samples with high-grade AIN included HPV56 in 3 sam-
ples, HPV51 in 2, HPV58 in 2, and HPV52, 59, 16, and
39 in one sample each. One sample from high-grade AIN
did not contain any of the twelve HPV genotypes offi-
cially recognized by the IARC as oncogenic, but con-
tained types 6, 53 and 73. The sample collected from the
participant with low-grade AIN also contained genotypes
6, 11, 18, 31, 35, 51, 52, 67, 73 and 89. HPV97-positive
samples contained more HPV genotypes (median 6,
range 2–10) than HPV97-negative samples (median 4,
range 1–11), although this difference was not statistically
significant (p = 0.12, Mann–Whitney test).HPV97 polymorphism analysis
In order to assess if the same isolate of HPV97 circulates
in the population of HIV-seropositive men living in
Montreal and Toronto, molecular variant analysis was
performed by direct PCR-sequencing of the complete
long control region (LCR) amplified from the 6 HPV97-
positive samples from Toronto and the 12 HPV97-
positive samples in which we had previously detected
HPV97 collected from the anal canal of HIV-
seropositive men living in Montreal [2]. Four HPV97
variants were defined by four variation sites in the LCR
(Table 1). All variants detected in Canada were different
from the one described initially by Burk et al. (Gene
Bank accession number EF436229) [1]. The variation
sites were located mainly in the 50-half of the LCR.
Three variants were detected from samples obtained in
Montreal while two were from samples obtained in To-
ronto. In both cities, the same variant was predominant.Discussion
HPV97 was first detected and cloned from a cervical
specimen from a women living in Costa Rica [4]. Since
then, HPV97 has been detected in only 1 of 734 women
living in Costa Rica and 1 of 1062 HIV-seropositive
women from the Women’s Interagency HIV Study con-
ducted in the US [4]. Could Canadian women be at
greater risk of HPV97 since this genotype had been
detected in Canadian men? The results of the current in-
vestigation support the low prevalence of HPV97 in
women, whether they are infected or at high risk for
HIV infection.
We had detected HPV97 sequences in 12 (4.9%) anal
swabs collected from 247 adult HIV-seropositive men
participating in the HIPVIRG cohort in Montreal,
Canada [2,5]. We now report a similar prevalence of
HPV97 in HIV-seropositive men from Toronto. In our
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cipants had biopsy-confirmed AIN [2], similarly to the
current report. Due to the presence of multiple type
infections in these HPV97-positive individuals with
high-grade AIN, it is not clear which of the infecting
types contributed to the development of AIN.
Our analysis of the LCR sequence suggests that several
variants of HPV97 are being transmitted in the anal
canal between HIV-seropositive men from Montreal or
Toronto. It is thus unlikely that HPV97 is a local epi-
demic restricted to the Montreal area. We cannot ex-
clude that men living in Toronto were infected by
HPV97 during a visit to Montreal. Moreover, the
complete LCR was analyzed and variations other than
C7194T, detected in all our isolates, were confirmed by
a second PCR-sequencing reaction to exclude PCR arti-
facts. The LCR is a non-coding segment that is less
restricted in its ability to accumulate and tolerate varia-
tions than HPV genes, and consequently is the area of
the HPV genome with the highest level of variation [6].
There is less genetic variability in E6 and E7 genes than
in the LCR [7-11]. Thus, the LCR is the region of the
HPV genome most often utilized for the classification of
molecular HPV variants [7].
Since HPV97 was not detected in cervicovaginal cells
from HIV-seropositive women, it would be worthwhile
to investigate its prevalence in anal samples from
HIV-seropositive and seronegative women, as well as
HIV-seronegative men. The analysis of HPV97 infec-
tion in men should be completed by detection of
HPV97 in penile samples from HIV-seropositive and
HIV-seronegative men. These studies would address if
this anogenital genotype infects preferentially males
and very rarely females, which would be unique for an
anogenital type. HPV97 frequently co-infects the anal
canal with other HPV types, which will complicate the
attribution of disease to this genotype.
Material and methods
The Canadian Women’s HIV study
Cell lysates were selected from stored CVL collected
from participants in the Canadian Women’s HIV Study
[3]. The first ß-globin-positive sample from each HIV-
seropositive woman and samples from HIV-seronegative
women living in Montreal were tested for HPV97. The
original study design and cohort characteristics have
been described elsewhere [3,10,12]. The research proto-
col was approved by Ethics committee of the Centre
Hospitalier de l’Université de Montréal.
Description of the Toronto cohort
Participants were part of the Toronto Research for Anal
Cancer Evaluation (TRACE) anal cancer screening study
[13]. The study was approved by the Research EthicsBoard of the University Health Network. Participants were
HIV-infected men aged 18 years or more with a history of
anal receptive intercourse and who were attending tertiary
care hospital HIV clinics in Toronto. HPV detection was
performed on a specimen collected by vigorously rotat-
ing a Dacron-tipped swab in the anal canal. The swab
was placed in liquid-based medium (Cytyc, Boxborough,
Massachusetts, USA). Sample DNA was extracted with a
Master Pure procedure as described previously [5].Detection of HPV97 with PCR
Two μl of processed DNA sample were used for
amplification with the HPV97-specific primers 50-
GAGCAGCCAGGTGTGGATA-30 and 50-CATGATT
ACCATCCATACACC-3 using a published protocol
[2]. Negative, weakly positive (10 HPV97 DNA cop-
ies), and strongly positive controls (1,000,000 HPV97
copies) were included in each run. Measures to avoid
false-positive reactions due to contamination were fol-
lowed strictly.
The presence of HPV97 DNA in samples generating a
PCR product of the expected size of 232 bp on gel elec-
trophoresis was confirmed by digesting the amplicon
into 138 and 94 bp fragments with the restriction en-
zyme Dde I [2] and, in parallel, by direct sequencing. Se-
quencing of the 232 bp amplicons was performed with
the same primers described above using the fluorescent
cycle-sequencing method (BigDye terminator ready re-
action kit, Perkin-Elmer) on an ABI Prism 3100 Genetic
Analyzer system. For 28 samples, HPV97 amplification
generated only a faint band of ±232 bp or a smear in
the area of the specific band. These samples were fur-
ther evaluated with the following nested PCR approach.
After an initial 20 cycle amplification with the HPV97-
specific primers described above, 10 μl of the amplified
mixture was further amplified with nested primers
50-GCAAAACGACGTCTGTTC-30 and 50-CCACTACT
ACATAAACTGCCG-30 using the amplification profile
described above. The presence of HPV97 DNA in these
samples was confirmed upon detection of a 128 bp spe-
cific fragment following 40 cycles of amplification.
HPV97 isolates were further characterized by direct
sequencing of PCR products encompassing the complete
LCR. Two overlapping fragments of the LCR were
amplified with primer pairs 50-CTACTACTTCCAAACC
TGCTAAG-30/50-TTTGCAATAGTGCCAGTACA-30 and
50-TGTAGATTCTGGCACTGTTG-30/50-ATATACACC
AGTTTCGGTTG-30. PCR-sequencing was performed
using the same primers with 20 ng of purified amplicons.
If PCR-sequencing revealed the presence of a novel vari-
ation, PCR sequencing was repeated to confirm the pres-
ence of the novel mutation. Unconfirmed mutations were
considered to be PCR artifacts.
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